NextPharma Technologies Board appoints Richard Milbank as Chief Financial Officer
London, UK – 10 April 2006
NextPharma Technologies - a leading provider of product development and manufacturing outsourcing services to the biotech and pharmaceutical industry, has appointed Richard Milbank as its Chief Financial Officer.
Richard was appointed as Executive Vice President - Chief Financial Officer with effect from 1st April 2006 having joined NextPharma in February 2004 as Senior Vice President Finance & Corporate Controller. He has considerable experience in process manufacturing gained over nine years, as the Financial Director of Huntsman Packaging and Key Country Foods Limited. Richard is a Chartered Accountant by background and has worked in the accountancy profession for nine years with Arthur Andersen and PricewaterhouseCoopers.
“Richard has demonstrated strong financial and commercial skills during his two years with NextPharma commented Bill Wedlake, CEO, NextPharma Technologies, these skills will help ensure that NextPharma continues to grow and develop on a sound financial basis and will remain at the forefront of providing timely, competitive, healthcare outsourcing solutions.”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principal shareholder is Credit Suisse First Boston Private Equity.
NextPharma Technologies Executive Vice President Dr. Hermann Osterwald is appointed to the Board of APV
London, UK –10th April 2006
NextPharma Technologies - a leading provider of product development and manufacturing outsourcing services to the biotech and pharmaceutical industry, is delighted to report that Dr Hermann Osterwald has been appointed as the treasurer of the International Association for Pharmaceutical Technology (APV) at a ceremony at the 5th World Meeting On Pharmaceutics Biopharmaceutics and Pharmaceutical Technology – in Geneva on 28th March 2006.
Dr. Hermann Osterwald who has been a member of APV since 1977 has gained considerable experience in a variety of senior roles within the Pharmaceutical industry dating back to 1981. He became a managing director for subsidiaries of the GEHE group in 1992. In 1998 he became Managing Partner of allphamed PHARBIL Arzneimittel GmbH in Göttingen and in 2000 he was appointed as Managing Director of Pharbil Industries GmbH (now NextPharma GmbH). Most recently Dr. Osterwald became the Executive Vice President Operations of NextPharma Technologies in 2003.
“Dr. Hermann Osterwald is a highly valued colleague, his pharmaceutical knowledge and expertise has been of critical importance to the development of NextPharma. Hermann has been a staunch supporter and promoter of all scientific development and innovation for many years and is widely respected in the industry for his contribution - commented Bill Wedlake, CEO, NextPharma Technologies.
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principal shareholder is Credit Suisse First Boston Private Equity. Most recently NextPharma is the winner of the Frost & Sullivan 2006 Growth Strategy Leadership Award for the European Pharmaceutical Contract Manufacturing for its demonstration of exceptional growth strategy within the industry.
About APV
APV is the pharmaceutical association in German speaking countries and in Europe, for all involved in the field of pharmaceuticals providing a platform for sharing and spreading scientific information related to pharmaceuticals. Every year APV conducts some 100 programmes of various types, ranging from international conferences through expert meetings and workshops for practicing pharmaceutical scientists and pharmacists to botanical expeditions.
NextPharma Technologies Establishes New Development Centre in Braine l’Alleud - Brussels
London, UK – 4th April 2006
NextPharma Technologies - a leading provider of product development and manufacturing outsourcing services to the biotech and pharmaceutical industry is delighted to report the establishment of a new Development Centre for sterile product dosage forms at its Braine l’Alleud site near Brussels, Belgium.
The facility will be operational in mid 2007 and will provide a comprehensive service for early phase development of sterile dosage forms for Cytostatic, Biologics, other conventional drugs and diluents in a wide range of drug delivery forms including - pre-filled syringes, cartridges, vials, ampoules and assembly of kits. All clinical materials will be manufactured and supplied in accordance with the requirements of US FDA, EMEA and other regulatory
agencies. The facility’s analytical laboratories will also provide a full range of biological and small molecular drug testing and conduct stability programmes according to ICH guidelines.
“NextPharma’s focus has always been to provide a full range of services to our customers and I’m delighted that the establishment of this facility will further our ability to do this as we will now be able to support our biologics customers” commented Bill Wedlake, CEO, NextPharma Technologies, “this facility will enable us to support our customers’ projects through pre-formulation work, formulation development and through to clinical development with scale-up capability in NextPharma’s manufacturing facilities at Braine l’Alleud, in accordance with the highest regulatory requirements.”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principle shareholder is Credit Suisse First Boston Private Equity. Most recently NextPharma is the winner of the Frost & Sullivan 2006 Growth Strategy
Leadership Award for the European Pharmaceutical Contract Manufacturing for its demonstration of exceptional growth strategy within their industry.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.